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BACKGROUND
The administration of endocrine therapy for 5 years substantially reduces recurrence 
rates during and after treatment in women with early-stage, estrogen-receptor (ER)–
positive breast cancer. Extending such therapy beyond 5 years offers further protection 
but has additional side effects. Obtaining data on the absolute risk of subsequent distant 
recurrence if therapy stops at 5 years could help determine whether to extend treatment.
METHODS
In this meta-analysis of the results of 88 trials involving 62,923 women with ER-posi-
tive breast cancer who were disease-free after 5 years of scheduled endocrine therapy, 
we used Kaplan–Meier and Cox regression analyses, stratified according to trial and 
treatment, to assess the associations of tumor diameter and nodal status (TN), tumor 
grade, and other factors with patients’ outcomes during the period from 5 to 20 years.
RESULTS
Breast-cancer recurrences occurred at a steady rate throughout the study period from 
5 to 20 years. The risk of distant recurrence was strongly correlated with the original 
TN status. Among the patients with stage T1 disease, the risk of distant recurrence 
was 13% with no nodal involvement (T1N0), 20% with one to three nodes involved 
(T1N1–3), and 34% with four to nine nodes involved (T1N4–9); among those with 
stage T2 disease, the risks were 19% with T2N0, 26% with T2N1–3, and 41% with 
T2N4–9. The risk of death from breast cancer was similarly dependent on TN status, 
but the risk of contralateral breast cancer was not. Given the TN status, the factors of 
tumor grade (available in 43,590 patients) and Ki-67 status (available in 7692 patients), 
which are strongly correlated with each other, were of only moderate independent 
predictive value for distant recurrence, but the status regarding the progesterone recep-
tor (in 54,115 patients) and human epidermal growth factor receptor type 2 (HER2) 
(in 15,418 patients in trials with no use of trastuzumab) was not predictive. During the 
study period from 5 to 20 years, the absolute risk of distant recurrence among patients 
with T1N0 breast cancer was 10% for low-grade disease, 13% for moderate-grade 
disease, and 17% for high-grade disease; the corresponding risks of any recurrence or 
a contralateral breast cancer were 17%, 22%, and 26%, respectively.
CONCLUSIONS
After 5 years of adjuvant endocrine therapy, breast-cancer recurrences continued to 
occur steadily throughout the study period from 5 to 20 years. The risk of distant recur-
rence was strongly correlated with the original TN status, with risks ranging from 10 
to 41%, depending on TN status and tumor grade. (Funded by Cancer Research UK 
and others.)
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In estrogen-receptor (ER)–positive early-stage breast cancer, 5 years of adjuvant endocrine therapy substantially reduces the 
risks of locoregional and distant recurrence, 
contralateral breast cancer, death from breast 
cancer, and hence death from any cause.1-3 In 
trials of 5 years of tamoxifen therapy versus no 
endocrine therapy, the recurrence rate in the 
tamoxifen group was approximately 50% lower 
than that in the control group during the first 
5 years (the treatment period) and approximately 
30% lower during the next 5 years. The rate of 
death from breast cancer in the tamoxifen group 
was approximately 30% lower than that in the 
control group during the first 15 years (i.e., includ-
ing 10 years after the cessation of therapy).2 In 
trials comparing an aromatase inhibitor versus 
tamoxifen in postmenopausal women, the aroma-
tase inhibitor was even more effective than 
tamoxifen, with about one third fewer recur-
rences during the treatment period (but with 
little further gain thereafter) and with approxi-
mately 15% fewer deaths from breast cancer 
during the first decade.3
Extending adjuvant endocrine therapy (with 
either tamoxifen or an aromatase inhibitor) be-
yond 5 years can further reduce recurrence.4-9 
For some women, however, receiving endocrine 
therapy for 5 years causes appreciable side effects, 
such as menopausal symptoms and arthropathy, 
which could continue with extended treatment.9-11 
Much less common, but potentially life-threaten-
ing, side effects of adjuvant endocrine therapy 
include pulmonary embolus and endometrial 
cancer associated with tamoxifen and osteopo-
rotic fracture associated with aromatase inhibi-
tors, and the cumulative risk of these toxic 
events increases with longer treatment.2,3,5,6,9
Thus, decisions about extending adjuvant endo-
crine therapy after 5 years without any recur-
rence need to balance additional benefits against 
additional side effects. Since the proportional 
reduction in recurrence from a given regimen 
appears to be approximately similar in different 
risk groups,2,3,6 the absolute benefits of continu-
ing endocrine therapy after 5 years depend on the 
absolute risk of later recurrence if no further 
therapy is given. Here, we report the influence of 
various characteristics of the original tumor on 
the 20-year incidence of breast-cancer outcomes 
in women with ER-positive, early-stage breast 
cancer who were scheduled to receive adjuvant 
endocrine therapy for 5 years and then to stop 
therapy. Our meta-analysis combines individual 
patient data from 88 trials in the Early Breast 
Cancer Trialists’ Collaborative Group (EBCTCG) 
database of randomized trials.
Me thods
Patients
We analyzed data from women who had ER-
positive breast cancer that had been diagnosed 
before the age of 75 years and who had T1 dis-
ease (tumor diameter, ≤2.0 cm) or T2 disease 
(tumor diameter, >2.0 to 5.0 cm), fewer than 10 
involved nodes (stratified according to a patho-
logical nodal status of no nodes [N0], 1 to 3 nodes 
[N1–3], or 4 to 9 nodes [N4–9]), and no distant 
metastases. All the patients were scheduled to 
receive endocrine therapy for 5 years then stop, 
regardless of actual adherence. Most of the pa-
tients entered the study at the time of diagnosis, 
but some entered later, having already received 
2 to 5 years of endocrine therapy, but were sched-
uled to stop therapy at 5 years.
Main Outcomes
The main outcomes were the rate of distant re-
currence (as defined by each trial), regardless of 
any local or contralateral events; the rate of any 
breast-cancer event (distant recurrence, loco-
regional recurrence, or contralateral new pri-
mary tumor, regardless of unrelated deaths); 
and the rate of death from breast cancer, as es-
timated by means of log-rank subtraction (i.e., 
subtracting the log-rank statistics from analyses 
of death without recurrence from causes other 
than breast cancer from the log-rank statistics 
for any death), as in previous EBCTCG reports.1-3
Study Oversight
All the authors participated in designing the 
study, writing the manuscript, and making the 
decision to submit the manuscript for publica-
tion. The members of the EBCTCG secretariat 
collected and analyzed the data and vouch for 
the accuracy and completeness of the data and 
analyses. No commercial sponsors or confiden-
tiality agreements were involved.
Statistical Analysis
We used Kaplan–Meier analyses to assess the as-
sociations of breast-cancer outcomes with tumor 
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diameter and nodal status. To smooth single-
year irregularities in Kaplan–Meier analyses, for 
some subgroups we estimated the event rate in 
a particular time period as the rate (first event 
per patient-year) for that whole period. We used 
Cox regression analyses, stratified according to 
tumor and nodal (TN) status, to assess the asso-
ciations of event rate ratios with age (<35, 35 to 
44, 45 to 54, 55 to 64, and 65 to 74 years at di-
agnosis) and, when available, with tumor grade 
(low, moderate, or high), Ki-67 antibody expres-
sion (a marker of proliferation in early breast 
cancer: 0 to 9%, 10 to 19%, or ≥20%), and status 
with respect to progesterone receptor and human 
epidermal growth factor receptor type 2 (HER2). 
All the analyses were stratified according to 
trial and study group, if more than one study 
group was assigned to receive 5-year endocrine 
therapy. For multigroup comparisons, the variance 
of the log risk in each group was calculated12 
and used to obtain group-specific confidence 
intervals for rate ratios.
R esult s
Characteristics of the Patients
Of the 500,692 women in the EBCTCG trials 
database, 114,867 had ER-positive, early-stage 
breast cancer and had been scheduled to receive 
endocrine therapy for 5 years and then stop. Of 
these women, 63% had been assigned to receive 
tamoxifen, 17% to receive an aromatase inhibi-
tor, and 20% to receive some sequence of tamox-
ifen and an aromatase inhibitor (Fig. 1). After 
the exclusion of patients who were 75 years of 
age or older at the time of diagnosis, those who 
had a tumor diameter of more than 5.0 cm, 
those who had more than 9 involved lymph 
nodes, and those with missing data with respect 
to age or TN status, a total of 74,194 women (in 
78 trials) had entered a study at the time of di-
agnosis and were included in analyses that be-
gan at year 0. We included an additional 10,200 
women who had entered the study later (at 2, 3, 
or 5 years) only in analyses that began at year 5, 
for a total of 62,923 women in 88 trials who 
were still being followed at 5 years without re-
currence or a second cancer.
The characteristics of the women in the study 
are provided in Table S1 in the Supplementary 
Appendix, available with the full text of this article 
at NEJM.org. Approximately 50% of the women 
had received a diagnosis of breast cancer before 
2000 (range, 1976 to 2011). All the women had 
data on age and TN status. Data were available 
regarding tumor grade in 43,590 of the patients 
(69%), progesterone-receptor status in 54,115 
(86%), HER2 status (regardless of the use of 
trastuzumab) in 24,145 (38%), and Ki-67 status 
in 7692 (12%). No gene-expression profiles were 
available. Similar numbers of women had under-
gone breast-conserving therapy and mastectomy; 
all the women had undergone lymph-node dis-
section. Approximately three quarters of those 
with node-positive disease had undergone chemo-
therapy. The receipt of chemotherapy was strong-
ly correlated with nodal status and, in N0 disease, 
with tumor diameter and grade. Only a quarter 
of those with known HER2-positive disease had 
been scheduled to receive trastuzumab (Table S2 
in the Supplementary Appendix).
Analyses of Data Starting at Year 0
The cumulative risk and annual rates of distant 
recurrence and death from breast cancer in each 
5-year period from year 0 to year 20, subdivided 
according to nodal status at the time of diagno-
sis, are shown in Figure 2. Within each category 
of nodal status, distant recurrences occurred 
steadily throughout the 20-year period. The an-
nual risk was strongly related (P<0.001) to nodal 
status, with a 20-year risk of distant recurrence 
of 22% in women with no positive nodes, 31% in 
those with one to three positive nodes, and 52% 
in those with four to nine positive nodes.
As expected in a population that was initially 
free of recurrence, the annual rates of death from 
breast cancer were low during the first 5 years 
(only about half the rates of distant recurrence). 
However, starting at year 5, the annual rates of 
death and distant recurrence were similar and 
the cumulative risk of death from breast cancer 
lagged behind that of distant recurrence by only 
a few years. Hence, the 20-year risks of death 
from breast cancer were 15% with N0 disease, 
28% with N1–3 disease, and 49% with N4–9 
disease — risks that were not much lower than 
the 20-year risks of distant recurrence.
Analyses Starting at Year 5
Cumulative risks and annual rates of distant re-
currence in each 5-year period during the period 
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Figure 1. Selection of Women with Breast Cancer from 88 Trials of Adjuvant Breast-Cancer Therapy.
The analyses combine individual patient data from 88 trials in the Early Breast Cancer Trialists’ Collaborative Group 
(EBCTCG) database of randomized trials. All the women who were included in the study were scheduled to receive 
adjuvant endocrine therapy for only 5 years, regardless of actual adherence, after a diagnosis of estrogen-receptor 
(ER)–positive breast cancer before the age of 75 years. A total of 74,194 women who were enrolled in 78 trials at the 
time of diagnosis were included in the analyses that began at year 0. A total of 62,923 women who were enrolled in 
88 trials either at the time of diagnosis or later (having already received 2 to 5 years of endocrine therapy) were 
scheduled to stop therapy at 5 years and were included in the analyses that began at year 5.
114,867 Who had ER-positive disease were scheduled
to receive endocrine therapy for only 5 yr
72,024 Were assigned to receive tamoxifen only
19,798 Were assigned to receive aromatase inhibitor
22,633 Were assigned to receive tamoxifen and
aromatase inhibitor
412 Were assigned to receive toremifene only
500,692 Women were included in the 
EBCTCG database in December 2016
62,923 Who were enrolled in 88 trials, who were
scheduled to stop endocrine therapy at 5 yr, and who
were still event-free and being followed at yr 5 were
included in the analyses that began at yr 5
385,825 Were excluded
156,610 Were ER-positive but were not scheduled
to receive endocrine therapy, or underwent
 <5 yr or >5 yr of endocrine therapy
103,834 Were ER-negative
125,381 Had unknown ER status
99,075 Entered at diagnosis, were assigned
to endocrine therapy, and were scheduled
to stop therapy at 5 yr
15,792 Entered later, during or at end
of endocrine therapy, and were scheduled
to stop therapy at 5 yr
24,881 Had missing data or were
ineligible
5,800 Had unknown age at  
diagnosis or were ≥75 yr
14,154 Had unknown tumor
diameter or had diameter
>5.0 cm
4,901 Had unknown no. of nodes
or had ≥10 nodes
26 Had missing entry
or follow-up date
74,194 Who were enrolled in 78 trials and
who entered at diagnosis were included
in analyses that began at year 0
10,200 Who were enrolled in 10 trials and
who entered later were not included
in analyses that began at year 0
5592 Had missing data or were
ineligible
632 Had unknown age at  
diagnosis or were ≥75 yr
3373 Had unknown tumor
diameter or had diameter
>5.0 cm
1570 Had unknown no. of nodes
or had ≥10 nodes
17 Had missing entry
or follow-up date
20,656 Had recurrence or second
cancer, died, or ended follow-up
before 5 yr
815 Had recurrence or second
cancer, died, or ended follow-up
before 5 yr
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from 5 to 20 years for the 62,923 women who 
reached year 5 without breast-cancer recurrence or 
any second cancer and who were scheduled to dis-
continue endocrine therapy are shown in Figure 3. 
The results are presented separately for T1 and 
T2 tumors and are subdivided according to 
nodal status at diagnosis. Although all the 
women had been clinically disease-free for many 
years, the original tumor diameter and espe-
cially the original nodal status remained power-
ful determinants of late distant recurrence, even 
during the second decade after diagnosis. With-
in each TN-status category, distant recurrences 
continued to occur steadily throughout the period 
from 5 to 20 years.
Even for women with the best prognosis, the 
risks were appreciable. For those with T1N0 
disease, the annual rate of distant recurrence 
remained approximately 1% throughout the pe-
riod from 5 to 20 years, resulting in a cumulative 
risk of distant recurrence of 13% (Fig. 3A). The 
associations of tumor diameter and nodal status 
with the risk of distant recurrence during the 
period from 5 to 20 years were approximately 
additive, with a progressive increase from 13% 
for T1N0 to 41% for T2N4–9 disease (Fig. 3B). 
Similar results were observed for rates of death 
from breast cancer (Figs. S13 through S16 in the 
Supplementary Appendix).
To further explore the possibility of identify-
ing groups at very low risk, we subdivided the 
rates of distant recurrence and of any breast-
cancer event (distant, local, or contralateral) 
among women with T1N0 disease according to 
tumor grade and size (T1a or T1b [≤1.0 cm] vs. 
T1c [>1.0 to 2.0 cm]) (Fig. 4). Although both tu-
mor grade and tumor size significantly affected 
Figure 2. Association between Pathological Nodal Status 
and the Risk of Distant Recurrence or Death from Breast 
Cancer during the 20-Year Study Period.
Shown are data regarding the risk of distant recurrence 
(Panel A) and death from breast cancer (Panel B) among 
74,194 women with ER-positive T1 or T2 disease who 
were enrolled in 78 trials at year 0 and were scheduled 
to receive 5 years of endocrine therapy. (Data for an-
other 10,200 women who enrolled in 10 trials after year 
0 are not shown here.) The risk was calculated according 
to the patients’ pathological nodal status at the time of 
diagnosis: N0, N1–3, or N4–9. The number of events 
and annual rate are shown for the preceding period 
(e.g., data for years 0 to 4 are shown at 5 years). The  
I bars indicate 95% confidence intervals. The dashed 
lines indicate that the event rate is for the whole 5-year 
period, rather than for individual years, as is otherwise 
shown. The annual rate of death from breast cancer 
was estimated by subtracting the death rate in women 
without recurrence from the rate in all women.
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prognosis in T1N0 disease, even women with 
T1N0 tumors that were well differentiated or 
measured 1.0 cm or less in diameter (i.e., T1a or 
T1b) had appreciable recurrence rates through-
out the period from 5 to 20 years. For low-grade 
T1N0 disease, the absolute risk during the study 
period was 10% for distant recurrence and 17% 
for any breast-cancer event (distant, local, or con-
tralateral); the risks were similar for the com-
bined T1a and T1b N0 group.
Other Prognostic Factors
The importance of TN status as a determinant of 
the distant-recurrence rate, and the additional 
relevance of age, tumor grade, and various tumor 
markers, are described separately for recurrences 
during the first 5 years and for those during the 
subsequent 15 years (to year 20) (Fig. S5 in the 
Supplementary Appendix). The importance of 
TN status was similarly strong during both time 
periods, as was the importance of a young age 
at the time of diagnosis. In contrast, other fac-
tors that were of some additional relevance dur-
ing the first 5 years were of less, or no, addi-
tional relevance thereafter, given the TN status. 
Tumor grade and the presence of Ki-67 antibody 
(which were strongly correlated with each other) 
were important independent factors of prog-
nostic value during the first 5 years but were of 
only moderate relevance thereafter. Progesterone-
receptor status was independently prognostic 
during years 0 to 5 but not thereafter. Only 2% 
of all the women in the study were scheduled to 
receive trastuzumab (Table S2 in the Supplemen-
tary Appendix), but in trials with no scheduled 
trastuzumab, 20,648 women had known HER2 
status. Among these women, those with HER2-
positive tumors who did not receive trastuzumab 
had a worse prognosis than those with HER2-
negative tumors during years 0 to 5 but not 
thereafter.
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Figure 3. Association between Pathological Nodal Status 
and the Risk of Distant Recurrence during Years 5 to 20 
of the Study, According to Tumor Stage.
Shown are the data for 62,923 women with ER-positive 
disease who were enrolled in 88 trials of breast-cancer 
therapy and who initiated therapy either at year 0 or 
within the first 5 years, according to whether they had 
T1 disease (Panel A) or T2 disease (Panel B). All the 
women were scheduled to receive 5 years of endocrine 
therapy and were event-free and still being followed at 
year 5. The I bars indicate 95% confidence intervals. The 
dashed lines indicate that the event rate is for the whole 
5-year period, rather than for individual years, as is other-
wise shown. Data for the number of events and annual 
rate begin at 5 years, since the analysis of the risk of 
distant recurrence starts at year 5.
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Other Outcomes
Graphs showing the influence of age and tumor 
characteristics on absolute and relative risks of 
any breast-cancer event, death from breast can-
cer, locoregional recurrence, and contralateral 
breast cancer are provided in Figures S6 though 
S22 in the Supplementary Appendix. Locoregion-
al recurrence and death from breast cancer 
showed much the same dependence on risk fac-
tors as distant recurrence. However, these risk 
factors were of little relevance to the risk of 
contralateral breast cancer, which continued at a 
rate of approximately 0.3% per year after the 
cessation of endocrine therapy, independent of 
age or TN status (Figs. S11 and S12 in the Sup-
plementary Appendix). The risk of death without 
known recurrence depended chiefly on age but 
was also somewhat dependent on TN status, 
which suggests that some of these deaths were 
in fact from breast cancer and that approximately 
5 to 10% of distant recurrences had been missed 
in trial records (Fig. S23 in the Supplementary 
Appendix).
Discussion
Among women with ER-positive, early-stage 
breast cancer who were scheduled to receive only 
5 years of adjuvant endocrine therapy, distant 
recurrences occurred at a steady rate for at least 
another 15 years after the end of the 5-year treat-
ment period. Throughout this time, the original 
nodal status and tumor diameter remained re-
markably strong determinants of the annual recur-
rence rate (Table 1). However, even among women 
with small, node-negative (T1N0), low-grade 
tumors, there was a risk of distant recurrence of 
approximately 10% during years 5 to 20. TN sta-
tus was also a strong determinant of locoregional 
recurrence, although not of contralateral disease.
Given the TN status, the other risk factors 
were of limited additional prognostic relevance 
after the cessation of 5-year endocrine therapy. 
There was a strong association of tumor grade 
and Ki-67 status with the risk of distant recur-
rence during years 0 to 5 but only a moderate 
association during years 5 to 20. Data regarding 
Variable
Women Who Were 
Event-free at 5 Yr
Annual Rate of Distant 
Recurrence
Cumulative Risk 
from 5 Yr to 20 Yr
Total
Chemotherapy 
Scheduled 5 to <10 Yr 10 to 20 Yr
no. no. (%) percent percent
Nodal involvement
N0 28,847 9,136 (32) 1.0 1.1 15
N1–3 25,292 17,280 (68) 1.9 1.7 23
N4–9 8,784 6,664 (76) 3.9 2.8 38
Tumor diameter in N0 only
T1a or T1b: ≤1.0 cm 5,527 910 (16) 0.5 0.8 10
T1c: 1.1–2.0 cm 13,875 4,034 (29) 0.8 1.1 14
T2: 2.1–3.0 cm 6,700 2,859 (43) 1.5 1.4 19
T2: 3.1–5.0 cm 2,745 1,333 (49) 1.7 1.4 20
Tumor grade in T1N0 only
Low 3,524 401 (11) 0.4 0.8 10
Moderate 7,363 1,861 (25) 0.7 1.0 13
High 3,054 1,414 (46) 0.9 1.5 17
*  Data are for 62,923 women with T1 or T2 estrogen-receptor–positive disease with 0 to 9 positive nodes who were 
scheduled to receive 5 years of adjuvant endocrine therapy and were disease-free at year 5. Most of the women entered 
the study at the time of diagnosis, but some entered later, having already received 2 to 5 years of endocrine therapy, 
and were randomly assigned to stop therapy at 5 years. P<0.001 for all subgroup comparisons.
Table 1. Association of Tumor Size and Nodal Status and Grade with the Risk of Distant Recurrence in Years 5 to <10 
and in Years 10 to 20.*
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tumor grade and Ki-67 status were sometimes 
from local institutions, so accuracy could be 
variable, but both factors were strongly predic-
tive of 5-year risk, which suggests that these 
values were assessed with reasonable accuracy. 
Better assessments should better predict out-
come but would probably not alter the observed 
pattern of substantially weaker associations with 
distant recurrence after 5 years than before 5 years. 
Likewise, tumors that were negative for proges-
terone receptor had a worse prognosis during 
years 0 to 5 but not thereafter, given the TN 
status. The data set did not include gene-expres-
sion assays,13-17 which may be shown to predict a 
very low risk of distant recurrence even without 
further therapy for some women when long-term 
follow-up data become available.18 However, deci-
sions with respect to extending endocrine therapy 
will probably still depend on disease stage, so 
these findings will remain relevant.
Our main aim was to determine whether we 
could identify subgroups of women who stop 
endocrine therapy after 5 years in whom long-
term risks are so small that any additional bene-
fits from extended therapy would be unlikely to 
outweigh the additional side effects. However, 
even among women with T1N0 disease, the cumu-
lative risk of distant recurrence was 13% during 
years 5 to 20. Although reliable trial evidence is 
not yet available on the long-term effects of ex-
tending endocrine therapy for 5 additional years 
on mortality,5-9,19-21 an absolute reduction of a few 
percentage points in the risk of distant metasta-
ses over the next 15 years might well be possible 
even for such low-risk women, with correspond-
ingly greater absolute benefits for women with 
larger tumors or node-positive disease. Except 
for women who are older than 70 years of age or 
those in poor health, these probabilities will not 
be much attenuated by the risk of death from 
another cause, since in the absence of breast 
cancer, more than 80% of the women in the 
United States in reasonable health at the age of 
65 years would be expected to survive beyond 
the age of 80 years.
Meta-analyses of data from individual patients 
will eventually reconcile any apparently con-
flicting findings from the trials of extending 
endocrine therapy beyond 5 years, especially after 
5 years of aromatase inhibitor therapy.5-9,19-21 When 
these findings are available, the likely benefits 
of extending therapy will have to be weighed 
against uncommon but potentially life-threaten-
ing side effects, such as bone fracture for aroma-
tase inhibitors3 and pulmonary embolus and (for 
women with a uterus) endometrial cancer for 
tamoxifen.2,5,6 The risks of such side effects in-
crease with longer treatment, although the abso-
lute risk of death from them is low (<0.5%).5-9
In addition, tamoxifen and aromatase inhibi-
tors can cause bothersome but non–life-threaten-
ing side effects, including menopausal symptoms, 
arthropathy, and carpal tunnel syndrome, which 
adversely affect the quality of life. However, such 
symptoms are quite common even without endo-
crine therapy. In placebo-controlled trials7-10,22-24 
that have systematically sought patient-reported 
outcomes, women in the placebo group have re-
ported more than half as many episodes as those 
in the endocrine-therapy group, which highlights 
the importance of placebo control to assess many 
pharmacologic side effects. Trials have also shown 
little difference in discontinuation rates between 
endocrine therapy and placebo, although in clini-
cal practice substantial numbers of women dis-
continue adjuvant endocrine therapy prematurely 
because of symptoms.25,26 However, women who 
have already completed 5 years of endocrine 
therapy are less at risk for unexpected symptoms 
than those who are initiating therapy.
These findings underline the need to help 
women who are receiving endocrine therapy to 
discover whether any symptoms are actually 
caused or exacerbated by therapy. Such patients 
could try stopping treatment for short periods or 
switching from one agent to another.26 Switch-
ing between an aromatase inhibitor and tamoxi-
fen, or among various aromatase inhibitors, is 
safer than discontinuing therapy prematurely.3 
Adherence may also be helped by interventions 
that can mitigate some of the symptoms attrib-
uted to endocrine therapy,27 including nonhor-
monal interventions that reduce menopausal 
symptoms,28,29 musculoskeletal symptoms,30 sexual 
dysfunction,31,32 and osteoporosis.33
Our study has several limitations. First, the 
recurrence rates reported here are in women who 
were scheduled to receive 5 years of endocrine 
therapy, not in those who completed treatment. 
Only a few of the trials in our study provided 
detailed data with respect to adherence, but a 
substantial minority of women in trials of 5-year 
endocrine therapy did not complete their treat-
ment.2 Because 5 years of therapy is more effec-
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tive than only 2 years,1,2 the risks among women 
who actually completed 5 years of therapy would 
be somewhat lower than those in our study. 
However, an expected lower risk with greater 
adherence is to some extent counterbalanced by 
unreported breast-cancer events: the association 
between TN status and the rate of death without 
reported recurrence suggests that some of these 
deaths were from unreported breast cancer and 
that the rate of distant recurrence would have 
been higher by 5 to 10% with complete ascer-
tainment. Although a persisting recurrence risk 
among women with ER-positive breast cancer is 
well recognized,13-17,34 our study quantifies the 
20-year risk more reliably than previous studies, 
since it is large and has long follow-up. However, 
long follow-up means that most of the patients 
received the breast-cancer diagnosis well before 
2000. Since then, the prognosis for women in 
particular TN categories has somewhat improved 
owing to earlier diagnosis, more accurate tumor 
staging, and better surgical, radiation, and sys-
temic therapies. Gene-expression arrays have also 
been adopted to guide the use of chemotherapy 
in ER-positive disease, a factor that has somewhat 
affected the mix of patients receiving chemo-
therapy.35 However, it seems unlikely that such 
factors would have a substantive effect on the 
generalizability of our findings to current patients, 
since the use of chemotherapy in our cohort was 
similar to that in current practice (Table S2 in 
the Supplementary Appendix).36
Furthermore, we could not reliably assess the 
relevance of chemotherapy to prognosis after 
year 5, since the women who received chemother-
apy and those who did not receive chemotherapy 
differed in the extent of nodal involvement, tu-
mor size, tumor grade, and perhaps unrecorded 
selection factors. The relevance of chemotherapy 
to prognosis after year 5 is best assessed in meta-
analyses of the trials of chemotherapy, since 
randomization balances known and unknown 
risk factors between treatment groups. Previous 
EBCTCG meta-analyses have shown that most of 
the reduction in the recurrence rate with chemo-
therapy occurred in the first 5 years, with simi-
lar proportional reductions among women with 
ER-positive and ER-negative disease, but also in-
dicated further benefit in years 5 to 9 with more 
effective regimens.37 Thus, the risk of recurrence 
after 5 years may well be somewhat lower in 
women who receive contemporary chemotherapy 
than among those in our study.
In addition, only 2% of the women in our study 
received trastuzumab. Wider use of trastuzumab 
in women with HER2-positive disease might have 
improved prognosis after 5 years,38 although 
again such a hypothesis would be best evaluated 
by meta-analyses of trastuzumab trials. In trials 
without trastuzumab, the recurrence risk in years 
0 to 4 was higher for HER2-positive tumors than 
for HER2-negative tumors, but HER2 status was 
of little relevance to prognosis thereafter. Hence, 
although HER2 status was unknown for many 
tumors, the overall findings are applicable to 
women with ER-positive, HER2-negative disease 
(i.e., to most women with ER-positive disease).
In conclusion, even after 5 years of adjuvant 
endocrine therapy, women with ER-positive, early-
stage breast cancer still had a persistent risk of 
recurrence and death from breast cancer for at 
least 20 years after the original diagnosis. This 
finding has implications for long-term follow-up 
strategies and highlights the need for new ap-
proaches to reduce late recurrence. The risk could 
be somewhat reduced by extending the duration 
of endocrine therapy,5-11 with greater absolute 
benefits for those at highest risk for recurrence. 
A major predictor of risk is TN status, although 
even among women with large, strongly node-
positive tumors, most who complete 5 years of 
endocrine therapy will remain free of distant 
recurrence 20 years after diagnosis. However, 
even low-grade T1N0 disease carries an apprecia-
ble risk of distant recurrence and contralateral 
breast cancer, a risk that is sufficient for at least 
the consideration of extended endocrine therapy. 
Recognition of the magnitude of the long-term 
risks of ER-positive disease can help women and 
their health care professionals decide whether 
to extend therapy beyond 5 years and whether to 
persist if adverse events occur.
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